Background & Objectives Comparison of clinical outcomes across anticoagulation regimens
using different apixaban dosing or warfarin is not well-defined in patients with nonvalvular …

Background: There are no randomized data evaluating the safety or efficacy of apixaban for
stroke prevention in patients with end-stage kidney disease on hemodialysis and with atrial …

Background: Patients with atrial fibrillation and severely decreased kidney function were
excluded from the pivotal non–vitamin K antagonist oral anticoagulants (NOAC) trials …

Background: Lifelong oral anticoagulation, either with warfarin or a non–vitamin K
antagonist oral anticoagulant (NOAC), is indicated for stroke prevention in most patients with …

BACKGROUND: Recommendations for apixaban dosing on the basis of kidney function are
inconsistent between the US Food and Drug Administration and European Medicines …

Background and aims Patients with severely reduced kidney function have been excluded
from randomized controlled trials and data on the safety and efficacy of direct oral …

Background The use of warfarin in patients with atrial fibrillation (AF) and end-stage renal
disease (ESRD) has been implicated with efficacy and safety concerns. Evidence on the role …

Introduction The comparative cost-effectiveness of all oral anticoagulants approved up to
date has not been evaluated from the US perspective. The objective of this study was to …

Background This study compared the efficacy and safety of apixaban and warfarin in
patients with nonvalvular atrial fibrillation (NVAF) and end-stage renal disease (ESRD) on …

Objective Evidence is needed on the impact of anticoagulation therapy on kidney function in
patients with atrial fibrillation (AF). The objective of this analysis, which is part of the …